Surprising results from ADMIRE-II trial: Darvadstrocel efficacy in complex perianal fistulas 🔴DVS showed higher response rates than placebo, but not significantly 🟠Unexpectedly high placebo response 🟢DVS well tolerated, no new safety concerns #ECCO2024 #ECCO23 Y-ECCO

Did you know that a quarter of extra-intestinal manifestations (EIMs) of IBD occur even before IBD onset? Read about how to identify and prescribe effectively to manage these in a report from #ECCO23, which covers a talk on the latest guideline for EIM buff.ly/3VTfVSh.

#RSCAppliedInterfaces RSC Applied journals, Soft Matter & PCCP are happy to sponsor #ECCo23 Early Career Colloid Network!

Zlatan Mujagic MD PhD bioRxiv Shrinivas Bishu Robert Battat MD Seb Jonathan Segal Beatriz Gros ignacio catalan Aline Charabaty, MD, FACG, AGAF Dominik Bettenworth Gianluca Ianiro Great study indeed! Also just recently presented at #ECCO23 by Arno Bourgonje! Looking forward to the full paper WeersmaLab academic.oup.com/ecco-jcc/artic…

Comienza Javier P. Gisbert su presentación sobre Investigación Española en #ECCO23 durante #IBDHIGHLIGHTS un orgullo tantos estudios GETECCU TECCU EXIT DUMBO CECUM BUTTERFLY VACOVEII Éxito de colaboración! Unidad EII Gastro SANTIAGO participando en todos!

Research presented at #ECCO23 focused on resection in Crohn’s disease, the role of AI for scoring histological images in ulcerative colitis, and more. Read more from Dr Julien Schulberg and more: buff.ly/41mrWRY #MedTwitter #SoMeDocs #Gastroenterology

🇳🇱 National Post-#ECCO23 meeting 🎙️Talked about: 📌New #upadacitinib data 📌The heavily discussed #REPREIVO trial 📌 Anti-Integrin αvβ6 Autoantibodies that antedate #UC Dx (Alexandra Livanos, MD PhD) ➡️ Looking forward to my_UEG later this year 🇩🇰 and #ECCO24 🇸🇪 Y-ECCO

Vedolizumab in Crohn e colite ulcerosa, persistenza ed efficacia superiore agli anti-TNF. #ECCO23 pharmastar.it/sharepage.html…

Malattie infiammatorie croniche intestinali, vedolizumab più efficace di altri trattamenti biologici #ECCO23 PharmaStar | #ECM bit.ly/42IeysN

Malattie infiammatorie croniche intestinali, vedolizumab più efficace di altri trattamenti biologici #ECCO23 PharmaStar | #ECM bit.ly/42IeysN

Read Dr Juliette Loehry’s main takeaways for clinical practice from #ECCO23, including the changing global prevalence of IBD and correlation with metabolic syndrome, in the research briefing: highlights from the ECCO’23 congress buff.ly/40tptV7.

#ICYMI: At #ECCO23 Maria T. Abreu reported #Stelara (JanssenUS) induces #remission, response ‘reassuring for our #patients’ with #IBD #GITwitter #MedTwitter bit.ly/40iXsPZ

In a Healio #GI #video exclusive, Maria T. Abreu outlined long-term data presented at #ECCO23 on the use of #Stelara (JanssenUS) among #patients with #IBD #GITwitter #MedTwitter bit.ly/40iXsPZ

1/3 Here are our top clinical 3 abstracts for #ECCO23 for IBDupdate.ca CAG Jeffrey McCurdy MD PhD @#MondayNightIBD #1 Vedolizumab is effective in preventing post operative recurrence! Should we use vedo instead of anti TNF? Miguel Regueiro

1/Who else is 📌 their Feb🗓️ for #ECCO24🇸🇪 ? 1st time Y-ECCO #ECCO23🇩🇰& realized it was the best kept #IBD secret! 🔥Dynamic leadership 👌🏽Scientific sessions 💭Provoking research 👩🏽‍🏫👨🏻‍🏫Diverse speakers & perspectives 👩🏼‍⚕️#WomenInGI well represented 🌍Network & Friendships💃🏻

#ICYMI from #ECCO23: New #Skyrizi, #Rinvoq (AbbVie) data will help ‘shape clinical practice’ in #IBD management Remo Panaccione, MD, FRCPC #GITwitter #MedTwitter bit.ly/3ZZGmqi

Exciting talk by #KalineArnauts IBD Leuven at #ECCO23 on #Organoids as a model to study IBD - ✅ advantages,❗️limitations and future outlook with gut-on-chip as a potential tool to integrate 🧫epithelial cells, immune cells and the microbiome 🦠